Advanced wound care solutions for multi-drug resistant infections and hemorrhage control in battlefield conditions

Memsel Inc. received a $4.52M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 1, 2025, with a completion date of August 31, 2027. The grant supports the development of advanced wound care solutions specifically designed to address multi-drug resistant infections and hemorrhage control in battlefield conditions. The research and development effort will leverage Memsel Inc.'s established expertise in biomedical technologies, particularly its specialized knowledge in sophisticated drug delivery systems and hydrogel-based medical interventions.

The deliverables under this project grant are expected to produce innovative biomedical solutions that can transform healthcare approaches for military service members in high-stress, combat environments. Drawing on the company's previous work developing hydrogel-based drug delivery systems and bacteriophage-encapsulated treatments for drug-resistant bacterial infections, this award funds the translation of these core competencies into battlefield-applicable wound care technologies. The two-year performance period aligns with typical Military Medical Research and Development program awards, which generally range from two to four years and fund hypothesis-driven research addressing critical military health priorities and broader public health objectives.